June 2 (Reuters) - Vera Therapeutics Inc VERA.O:
VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHY
VERA THERAPEUTICS INC - TO SUBMIT BLA FOR ATACICEPT TO FDA IN 4Q 2025
VERA THERAPEUTICS INC - ATACICEPT SAFETY PROFILE FAVORABLE AND COMPARABLE TO PLACEBO
VERA THERAPEUTICS INC: PRIMARY ENDPOINT WAS MET IN ORIGIN PHASE 3 TRIAL OF ATACICEPT
Source text: ID:nGNX8QnTwP
Further company coverage: VERA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.